CARDENE SR
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Feb 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
CARDENE SR by Chiesi is mechanism of action nicardipine is a calcium entry blocker (slow channel blocker or calcium ion antagonist) that inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. Approved for hypertension. First approved in 1992.
Drug data last refreshed 21h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDENE SR (nicardipine) is an extended-release oral calcium channel blocker approved in 1992 for hypertension management. It selectively inhibits calcium ion influx into vascular smooth muscle, producing vasodilation with minimal cardiac effects. The drug is indicated as monotherapy or adjunctive therapy for hypertension in adult patients.
LOE Approaching
As LOE approaches, the brand team will likely contract; focus shifts toward lifecycle management and cost-containment strategies rather than growth initiatives.
Mechanism of Action
Mechanism of Action Nicardipine is a calcium entry blocker (slow channel blocker or calcium ion antagonist) that inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. The contractile processes of cardiac muscle and…
Indications (1)
Career Relevance
CARDENE SR offers limited career growth opportunities due to LOE-approaching lifecycle status and competitive pressure score of 30/100. Roles focus on maintaining market share, managing payer relationships, and preparing for generic competition rather than expansion.
Worked on CARDENE SR at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.